Pharmaceutical intermediates

Irinotecan Intermediates

1 pharmaceutical intermediate for Irinotecan. Indication: Colorectal cancer; Colorectal carcinoma; Non-Hodgkin lymphoma; Non-small cell lung cancer; Lung cancer; Ovarian cancer.

Submit a Project All intermediates

About Irinotecan

Originator: Yakult Honsha Co., Ltd
Indication: Colorectal cancer; Colorectal carcinoma; Non-Hodgkin lymphoma; Non-small cell lung cancer; Lung cancer; Ovarian cancer
Approved Date: 06/14/1996

Available intermediates

1 intermediate currently listed for Irinotecan. Request specifications, documentation or a quotation for any item below.

Irinotecan intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
1-(2-Amino-5-hydroxyphenyl)propan-1-one	35364-15-9	/	/

Other programs under I

Ibrutinib/ Zanubrutinib Iguratimod Imatinib Imeglimin hydrochloride Indacaterol Maleate Infigratinib Ipatacopan Hydrochloride Ipragliflozin

Building toward Irinotecan?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here